Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
about
Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implicationsT Cell Migration in Rheumatoid ArthritisViews of healthcare professionals to linkage of routinely collected healthcare data: a systematic literature reviewRetention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation.Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.Applying evidence in the care of patients with rheumatoid hand and wrist deformities.Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic reviewRituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor.Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.Modeling rheumatoid arthritis using different techniques - a review of model construction and results.Are biological agents toxic to human chondrocytes and osteocytes?Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance.Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis.A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years.A 5-Year Cost-Effectiveness Analysis of Silicone Metacarpophalangeal Arthroplasty in Patients with Rheumatoid Arthritis.Effectiveness of golimumab in clinical management of patients with rheumatoid arthritisInvestigating the value of abatacept in the treatment of rheumatoid arthritis: a systematic review of cost-effectiveness studies.Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in BrazilEfficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsClinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.Administration costs of intravenous biologic drugs for rheumatoid arthritis.Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort StudyAbatacept: a review of its use in the management of rheumatoid arthritis.A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Adalimumab in the treatment of immune-mediated diseases.Rituximab for rheumatoid arthrits treatment: a systematic review.Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: A meta-analysis and systematic review.Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
P2860
Q26783490-355C5DD7-DD12-4573-8F8B-3C92F8D9E504Q26797338-E571B841-8687-42AA-AAC5-CE3ED6D7341BQ27008494-C19665D9-DAB0-40B1-9329-24608DA17566Q30991911-D622C5E9-1CA8-4013-BE57-146F7FFFB696Q33932158-99EC1F0F-EEC5-471A-9513-3975D9E52715Q33962865-A78EC904-9685-4A4D-B57E-6313C8C65988Q34149534-7EB9C97B-6438-4FFA-85C7-2CD79A6DDE6BQ35001257-ED1B53C8-905F-43FD-85AD-2B731EC406B1Q35188042-25A3A23D-F2A6-4D8D-A2D5-34E819C540F8Q35605438-F823B5E6-C502-4969-8763-7FC0217B6409Q35757007-87F69CBA-DFB0-4830-8C02-086A2B60F828Q35809549-74A52086-F76A-41BA-93E7-AF30D56955F5Q35835741-B9BAA5D2-8081-45B7-B6AF-81BAE21CD8CFQ35851012-AFB4FF43-2706-4F0C-914F-9C24A7936113Q35903134-4222F0DC-D106-4800-8800-EB6AA0270743Q35996191-F66A55E0-23A2-4E3E-A017-ED9CD865DB99Q36412824-D45F2255-D2D9-40FB-83A7-5A8E4D0E9F92Q36496107-A13B4046-2D79-4117-BA0D-BD56BA502D6CQ36720944-4EEBBF1E-31E5-48AB-A6CB-73BEABFB6444Q36767782-72A1A97A-76C0-4F9C-817C-F6DEB14D5156Q36931485-70959DE5-34BB-4150-ADC7-F0B658621D71Q36931621-B6D4C220-84A4-4345-88D3-38D8F5B33610Q37085663-BB416BAA-50A6-4219-9EDE-EB4A5D4CE2D7Q37143744-F0FB1232-B49A-45DC-89E8-B10B85ADCCB6Q37267285-556EDF58-E87A-42A3-87C8-4B39597D7E76Q37301258-281CC324-C2DA-42BD-9BFC-905ECDA5E976Q37452672-652419FF-C0F2-4EF2-B7DB-BAD527D09D6BQ37452967-35B55C5F-C515-40BC-B2DF-8B62F0B6F69DQ38116472-B9E8E3B5-5A2F-4708-8F54-7677968314A6Q38153099-ED9C72E4-053C-4667-AE2D-5F762EA46F28Q38170177-24B2FD28-118C-47F8-A7A7-07E105E8D0A8Q38185992-9930AF64-EFA1-4EF0-B790-EBEBD368ED97Q38207759-5B9DBD31-8BF3-4BDE-9222-0300816DD6B4Q38207760-BF444FF4-8D94-4E50-8F9E-4E3C8035DBAEQ38233120-AB6ED92D-0DC1-4497-8965-B0F49C3D7EB1Q38968920-08179AE3-3CD7-475C-8441-6A446E75B97FQ39068415-49CA49AB-2980-4F59-8AC3-FFC659D87430Q39646869-A545E527-725D-423F-BD87-0EAB3352F6D5Q40405513-BB15126D-FB08-4C9E-A73F-F78C615ED263Q40749335-94097386-4423-47EA-8AA1-1680612956F4
P2860
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@ast
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@en
type
label
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@ast
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@en
prefLabel
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@ast
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@en
P2093
P356
P1476
Adalimumab, etanercept, inflix ...... eview and economic evaluation.
@en
P2093
A Fry-Smith
A O Uthman
A Tsourapas
P Jobanputra
P356
10.3310/HTA15140
P577
2011-03-01T00:00:00Z